Cargando…

Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer

BACKGROUND: Molecular biomarker tests are developed as diagnostic tools for prostate cancer (PCa) diagnosis. The SelectMDx (MDxHealth, Nijmegen, The Netherlands) test is a urinary-based biomarker test intended to be used to predict presence of high-grade PCa upon biopsy in men with elevated serum pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Visser, Wieke C. H., de Jong, Hans, Steyaert, Sandra, Melchers, Willem J. G., Mulders, Peter F. A., Schalken, Jack A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385481/ https://www.ncbi.nlm.nih.gov/pubmed/35810263 http://dx.doi.org/10.1038/s41391-022-00562-1

Ejemplares similares

Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis
por: Visser, Wieke C. H., et al.
Publicado: (2020)

Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men
por: Hendriks, Rianne J., et al.
Publicado: (2021)

A SelectMDx/magnetic resonance imaging‐based nomogram to diagnose prostate cancer
por: Wagaskar, Vinayak G., et al.
Publicado: (2022)

Can the predictive value of multiparametric MRI for prostate cancer be improved by a liquid biopsy with SelectMDx?
por: Rahnama'i, Mohammad Sajjad, et al.
Publicado: (2021)

SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study
por: Maggi, Martina, et al.
Publicado: (2021)

Clinically significant Prostate Cancer diagnosed using a urinary molecular biomarker-based risk score: two case reports
por: Minnee, Pieter, et al.
Publicado: (2019)

PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis
por: Salagierski, Maciej, et al.
Publicado: (2010)

Prostate Cancer Liquid Biopsy Biomarkers’ Clinical Utility in Diagnosis and Prognosis
por: Matuszczak, Milena, et al.
Publicado: (2021)

Interplay between Exonic Splicing Enhancers, mRNA Processing, and mRNA Surveillance in the Dystrophic Mdx Mouse
por: Buvoli, Massimo, et al.
Publicado: (2007)

Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis
por: Luna Velez, Maria V., et al.
Publicado: (2019)

Personalized Management in Low-Risk Prostate Cancer: The Role of Biomarkers
por: Dijkstra, Siebren, et al.
Publicado: (2012)

Oxidative damage to urinary proteins from the GRMD dog and mdx mouse as biomarkers of dystropathology in Duchenne muscular dystrophy
por: Terrill, Jessica R., et al.
Publicado: (2020)

The need for a personalized approach for prostate cancer management
por: Sedelaar, JP Michiel, et al.
Publicado: (2015)

Noncoding RNAs as Novel Biomarkers in Prostate Cancer
por: Rönnau, C. G. H., et al.
Publicado: (2014)

Urinary mRNA biomarker panel for the detection of urothelial carcinoma
por: Urquidi, Virginia, et al.
Publicado: (2016)

Fast Track to MDX
por: Whitehorn, Mark, et al.
Publicado: (2005)

Delivery of antisense oligonucleotides for splice‐correction of androgen receptor pre‐mRNA in castration‐resistant prostate cancer models using cell‐penetrating peptides
por: Luna Velez, Maria V., et al.
Publicado: (2022)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

How accurate is our prediction of biopsy outcome? PCA3-based nomograms in personalized diagnosis of prostate cancer
por: Salagierski, Maciej, et al.
Publicado: (2012)

A comparison of the bone and growth phenotype of mdx, mdx:Cmah(−/−) and mdx:Utrn(+/−) murine models with the C57BL/10 wild-type mouse
por: Wood, Claire L., et al.
Publicado: (2020)

Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice
por: Ziemba, Michael, et al.
Publicado: (2021)

Biomarkers for Duchenne muscular dystrophy progression: impact of age in the mdx tongue spared muscle
por: Lorena, Marcelo dos Santos Voltani, et al.
Publicado: (2023)

Biomarkers for Duchenne muscular dystrophy progression: impact of age in the mdx tongue spared muscle
por: Lorena, Marcelo dos Santos Voltani, et al.
Publicado: (2023)

For what factors should we normalize urinary extracellular mRNA biomarkers?
por: Gunasekaran, Pradeep Moon, et al.
Publicado: (2019)

CTLA-4 based therapy (MDX-010)
por: Korman, A
Publicado: (2003)

Mutation Types and Aging Differently Affect Revertant Fiber Expansion in Dystrophic Mdx and Mdx52 Mice
por: Echigoya, Yusuke, et al.
Publicado: (2013)

Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy
por: Armandari, Inna, et al.
Publicado: (2014)

Identification of prostate cancer biomarkers in urinary exosomes
por: Øverbye, Anders, et al.
Publicado: (2015)

Urinary endogenous peptides as biomarkers for prostate cancer
por: De Souza Dutra, Cristine, et al.
Publicado: (2023)

The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse
por: Zhang, Aiping, et al.
Publicado: (2015)

Cost-effectiveness of an urinary biomarker panel in combination with MRI for prostate cancer diagnosis
por: Govers, Tim M., et al.
Publicado: (2023)

Erythropoietin reduces the expression of myostatin in mdx dystrophic mice
por: Feder, D., et al.
Publicado: (2014)

Affinity Captured Urinary Extracellular Vesicles Provide mRNA and miRNA Biomarkers for Improved Accuracy of Prostate Cancer Detection: A Pilot Study
por: Davey, Michelle, et al.
Publicado: (2020)

Circadian Genes as Exploratory Biomarkers in DMD: Results From Both the mdx Mouse Model and Patients
por: Rossi, Rachele, et al.
Publicado: (2021)

Chronic Dosing with Membrane Sealant Poloxamer 188 NF Improves Respiratory Dysfunction in Dystrophic Mdx and Mdx/Utrophin(-/-) Mice
por: Markham, Bruce E., et al.
Publicado: (2015)

Effects of Dantrolene Therapy on Disease Phenotype in Dystrophin Deficient mdx Mice
por: Quinn, James L, et al.
Publicado: (2013)

Approaches to the discovery of non-invasive urinary biomarkers of prostate cancer
por: Jedinak, Andrej, et al.
Publicado: (2018)

Effect of uphill running on myocardium T(2) in mdx mice
por: Forbes, Sean C, et al.
Publicado: (2012)

Sildenafil ameliorates cardiomyopathy in dystrophin-null (mdx) mice
por: Parchen, Candace M, et al.
Publicado: (2009)

Aquaporin 4 Expression in the mdx Mouse Diaphragm
por: Hara, Hajime, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_hi3ns8nf3b3psve73vco13ha1h